company background image
TOL

Toleranzia OM:TOL Stock Report

Last Price

kr0.95

Market Cap

kr104.8m

7D

-0.6%

1Y

-35.4%

Updated

30 Sep, 2022

Data

Company Financials
TOL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

TOL Stock Overview

Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases.

Toleranzia AB Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Toleranzia
Historical stock prices
Current Share Pricekr0.95
52 Week Highkr1.48
52 Week Lowkr0.82
Beta1.63
1 Month Change-2.66%
3 Month Change-7.32%
1 Year Change-35.37%
3 Year Change-80.85%
5 Year Change-80.96%
Change since IPO-89.50%

Recent News & Updates

Shareholder Returns

TOLSE BiotechsSE Market
7D-0.6%10.3%0.5%
1Y-35.4%-31.3%-27.6%

Return vs Industry: TOL underperformed the Swedish Biotechs industry which returned -30.9% over the past year.

Return vs Market: TOL underperformed the Swedish Market which returned -29.4% over the past year.

Price Volatility

Is TOL's price volatile compared to industry and market?
TOL volatility
TOL Average Weekly Movement8.1%
Biotechs Industry Average Movement8.1%
Market Average Movement6.9%
10% most volatile stocks in SE Market11.8%
10% least volatile stocks in SE Market4.3%

Stable Share Price: TOL is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: TOL's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20114Charlotte Friberthttps://www.toleranzia.com

Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease.

Toleranzia AB Fundamentals Summary

How do Toleranzia's earnings and revenue compare to its market cap?
TOL fundamental statistics
Market Capkr104.80m
Earnings (TTM)-kr7.54m
Revenue (TTM)kr32.74m

3.2x

P/S Ratio

-13.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TOL income statement (TTM)
Revenuekr32.74m
Cost of Revenuekr0
Gross Profitkr32.74m
Other Expenseskr40.28m
Earnings-kr7.54m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Oct 28, 2022

Earnings per share (EPS)-0.068
Gross Margin100.00%
Net Profit Margin-23.03%
Debt/Equity Ratio0.7%

How did TOL perform over the long term?

See historical performance and comparison